Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. Their use in the treatment of cancer

The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors. Particularly the present invention is related to therapeutic formulations able to increase the immunogenicity of...

Full description

Saved in:
Bibliographic Details
Main Authors LAGE DAVILA, AGUSTIN BIENVENIDO, MONTERO CASIMIRO, JOSÉ ENRIQUE, PEREZ RODRIGUEZ, ROLANDO JUAN DELGADO, ALONSO SARDUY, LIVÁN BLADIMIR CHAMARRO
Format Patent
LanguageEnglish
French
German
Published 08.07.2015
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors. Particularly the present invention is related to therapeutic formulations able to increase the immunogenicity of the IL-2 conjugated to the carrier protein P64k from the Neisseria Meningitidis in Montanide ISA 51 adjuvant for the induction of IL-2 neutralizing autoantibodies and the effective methods for the treatment of tumors, including breast cancer and melanoma. Furthermore, the present invention is related to therapeutic combination of the IL-2 based vaccine with other cancer vaccines based on specific tumor antigens or tumor growth factors, as well as chemotherapeutics agents or radiotherapy of standard use for cancer treatment.
Bibliography:Application Number: EP20090164216